__NUXT_JSONP__("/drugs/Vincristine_Sulfate", (function(a,b,c,d,e,f,g){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[{brand:b,indication:"INDICATIONS AND USAGE VINCASAR PFS is indicated in acute leukemia. VINCASAR PFS has also been shown to be useful in combination with other oncolytic agents in Hodgkin’s disease, non-Hodgkin’s malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor.",manufacturer:"Teva Parenteral Medicines, Inc.",splSetId:"01cee93f-3ab9-44fa-8c9a-dd5958fd2db9"},{brand:c,indication:d,manufacturer:e,splSetId:"49596de6-ab18-49d1-9e5b-30968fc21c36"},{brand:c,indication:d,manufacturer:e,splSetId:"b22e4c8e-dbe1-4d4b-a026-e1812974071c"}],id:a,nciThesaurus:{casRegistry:"2068-78-2",chebiId:"",chemicalFormula:"C46H56N4O10.H2O4S",definition:"The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.",fdaUniiCode:"T5IRO3534A",identifier:"C1739",preferredName:f,semanticType:"Organic Chemical",subclassOf:["C67422","C932"],synonyms:["Kyocristine","Leurocristine Sulfate","Leurocristine sulfate","Leurocristine, sulfate","Oncovin","VINCRISTINE SULFATE","Vincasar",b,"Vincosid","Vincrex",f,"Vincristine, sulfate","vincristine sulfate"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FVincristine_Sulfate",extension:".json",createdAt:g,updatedAt:g}}],fetch:{},mutations:void 0}}("Vincristine_Sulfate","Vincasar PFS","VinCRIStine Sulfate","INDICATIONS AND USAGE Vincristine sulfate injection is indicated in acute leukemia. Vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.","Hospira, Inc.","Vincristine Sulfate","2021-10-30T13:36:22.013Z")));